A consensus panel issued in 2008 recommended testing Lp-PLA2 not only as a diagnostic test for vascular inflammation but also in adjunct to traditional risk factor assessment in individuals with moderate or high risk of cardiovascular disease as defined by Framingham risk scores (16). The gene discussed is PLA2G7; the disease is cardiovascular disorder.